L. Popplewell

发表

Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?

S. Forman, M. Loscalzo, K. Clark, 2017, The Oncologist.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary anaplastic large-cell lymphoma associated with breast implants

K. Chang, S. Forman, Qin Huang, 2011, Leukemia & lymphoma.

Allogeneic hematopoietic stem cell transplantation for acute leukemia, chronic leukemia, and myelodysplasia.

S. Forman, L. Popplewell, 1999, Hematology/oncology clinics of North America.

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

J. Friedberg, J. Leonard, B. Cheson, 2015 .

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.

Christine E Brown, Wen-Chung Chang, S. Riddell, 2016, Blood.

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Xiuli Wang, S. Forman, Christine E. Brown, 2021, Blood advances.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

M. Kalos, S. Forman, M. Jensen, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma.

M. Kalos, S. Forman, M. Jensen, 2007 .

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials

B. Coiffier, S. Bates, S. Horwitz, 2017, Leukemia & lymphoma.

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative data

S. Steinberg, E. Jaffe, T. Litman, 2015, British journal of haematology.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

T. Habermann, Richard J. Jones, J. Herman, 2012, Blood.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Sonali M. Smith, J. Friedberg, L. Rimsza, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

L. Kwak, S. Rosen, P. Martin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

A. Nademanee, J. Bading, J. Wong, 2021, Blood advances.

Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.

J. Sancho, C. Buske, M. Ogura, 2021, Clinical Lymphoma, Myeloma & Leukemia.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Craig B. Davis, R. Houot, X. Mu, 2020, Clinical Cancer Research.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular andOther CD20þNon-Hodgkin Lymphomas

Craig B. Davis, R. Houot, X. Mu, 2020 .

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

P. Kaesberg, P. Frankel, S. Forman, 2020, Leukemia & lymphoma.

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.

B. Coiffier, J. Sancho, C. Buske, 2018, The Lancet. Haematology.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

A. Nademanee, A. Krishnan, S. Forman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: The Role of Histology

A. Nademanee, A. Krishnan, S. Forman, 2017 .

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2012 .

Late onset of EBV-driven PTLD/Burkitt lymphoma/leukemia in a patient 10 years after allogeneic stem cell transplant for AML

M. Slovak, S. Forman, L. Popplewell, 2010, Bone Marrow Transplantation.

Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study

Wan-Jen Hong, F. Morschhauser, M. Palomba, 2021, Clinical Lymphoma Myeloma and Leukemia.

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2005, Blood.

NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia

M. Slovak, H. Ahuja, L. Popplewell, 2001, Genes, chromosomes & cancer.

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

A. Nademanee, L. Kwak, Y. Nieto, 2020 .

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

J. Wright, P. Frankel, S. Forman, 2011, Leukemia.

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP

W. Chan, D. Weisenburger, D. Scott, 2020, Clinical Cancer Research.

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

R. Advani, Sonali M. Smith, I. Flinn, 2018 .

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

A. Nademanee, P. Frankel, S. Forman, 2015, Haematologica.

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.

A. Nademanee, A. Krishnan, M. Slovak, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

A. Nademanee, L. Kwak, I. Aldoss, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.

S. Horwitz, L. Popplewell, C. Franco, 2011, Clinical advances in hematology & oncology : H&O.

21q22 balanced chromosome aberrations in therapy‐related hematopoietic disorders: Report from an International Workshop †

M. Slovak, C. Schoch, D. Arber, 2002, Genes, chromosomes & cancer.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities

M. Slovak, D. Arber, V. Bedell, 2003, Leukemia.

A phase II trial 90y-ibritumomab tiuxetan in combination with reduced intensity regimen of fludarabine (flu) and melphalan (mel) followed by allo-HCT in patients with refractory B-cell lymphoma.

A. Nademanee, S. Forman, A. Raubitschek, 2012 .

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

J. Leonard, S. Forman, T. Siddiqi, 2014 .

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Y. Yen, P. Frankel, Kenneth K. Chan, 2016, Leukemia & lymphoma.

Non-Hodgkins Lymphoma (NHL) by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Combination with High-Dose Etoposide and Cyclophosphamide Followed A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL).

T. Habermann, L. Swinnen, H. Jacene, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Mismatch Repair Defects in the Familial Occurrence of Lymphoma and Colorectal Cancer

K. Offit, J. Teruya-Feldstein, N. Ellis, 2002, Leukemia & lymphoma.

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

P. Frankel, S. Forman, J. Tuscano, 2014 .

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

S. Groshen, J. Dipersio, J. Tuscano, 2019, Clinical Cancer Research.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

A. Nademanee, L. Kwak, Y. Nieto, 2022, The Lancet. Haematology.

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

A. Nademanee, P. Frankel, S. Forman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma. A California Cancer Consortium Study.

A. Nademanee, D. Gandara, P. Frankel, 2007 .

CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma

I. Weissman, R. Advani, Sonali M. Smith, 2018, The New England journal of medicine.

High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.

A. Nademanee, S. Forman, K. Gaal, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control

A. Nademanee, S. Forman, D. Senitzer, 2011, Leukemia & lymphoma.

PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

B. Coiffier, S. Horwitz, N. Bartlett, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

A. Nademanee, A. Krishnan, S. Forman, 2006 .

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.

S. Forman, M. Jensen, L. Cooper, 2003, Blood.

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

M. Kersten, P. Riedell, R. Malladi, 2021, Nature Medicine.

Oral complications of cancer and cancer therapy

J. Thariat, J. Epstein, A. Barasch, 2012, CA: a cancer journal for clinicians.

The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Jinhui Wang, Xiwei Wu, Xiuli Wang, 2020, Cancer Immunology Research.

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

W. Plunkett, W. Wierda, S. Coutre, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study

Michael L. Wang, M. Kaminski, J. Winter, 2014, British journal of haematology.

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

R. Jove, Y. Yen, A. Scuto, 2011, Leukemia.

Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.

V. Ribrag, J. Westin, F. Morschhauser, 2021, Clinical lymphoma, myeloma & leukemia.

Chromosomal and gene amplification in diffuse large B-cell lymphoma.

J. Cigudosa, K. Offit, S. Jhanwar, 1998, Blood.

Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

P. Hari, M. Pasquini, M. Qazilbash, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

S. Kambhampati, T. Siddiqi, A. Salhotra, 2022, Clinical lymphoma, myeloma & leukemia.

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

P. Vyas, B. Graves, M. Andreeff, 2015, Clinical Cancer Research.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Sonali M. Smith, J. Friedberg, L. Rimsza, 2015, American journal of hematology.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

A. Nademanee, J. Rossi, L. Kwak, 2018, Journal of Hematology & Oncology.

Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

A. Nademanee, A. Krishnan, G. Somlo, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

R. Crystal, S. Harper, L. Zoloth, 2014, Human gene therapy.

Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.

P. Frankel, G. Somlo, S. Forman, 2022, Transplantation and cellular therapy.

Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.

An Liu, T. Schultheiss, J. Wong, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

P. Vyas, L. Vassilev, Suzanne Cheng, 2012 .

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Scott E. Smith, R. Larson, W. Stock, 2013, Clinical Cancer Research.

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

W. Chan, D. Weisenburger, L. Kwak, 2019, Blood.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (B Cell)

G. Laport, L. Popplewell, 2016 .

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

M. Angelopoulou, G. Somlo, S. Forman, 2004, Bone Marrow Transplantation.

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies

A. Nademanee, A. Krishnan, S. Bhatia, 2012, Leukemia.

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

A. LaCasce, I. Flinn, N. Bartlett, 2019, Hematological Oncology.

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

L. Staudt, W. Wilson, S. de Vos, 2021, Leukemia & lymphoma.

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

S. de Vos, D. Miklos, L. Lekakis, 2021, Blood.

Total Marrow Irradiation Using hree-Dimensional Image-Guided Tomographic ntensity-Modulated Radiation Therapy : An lternative to Standard Total Body Irradiation

Anthony Stein, Stephen Forman, Joseph Rosenthal, 2006 .

Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

A. Nademanee, J. Leonard, Bihong T. Chen, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.

L. Lekakis, S. Neelapu, F. Locke, 2021 .

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

W. Chan, D. Weisenburger, A. LaCasce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).

Scott E. Smith, R. Larson, W. Stock, 2012 .

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

A. Nademanee, S. Forman, J. Rosenthal, 2011, Annals of Hematology.

Lymphoma

L. Popplewell, 2019, Oncology in the Precision Medicine Era.

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

A. Nademanee, S. Forman, T. Siddiqi, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics

S. Bhatia, S. Forman, G. Uman, 2012, Supportive Care in Cancer.

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

B. Barlogie, R. Orlowski, G. Srkalović, 2014, Cancer medicine.

Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?

A. Nademanee, A. Krishnan, M. Slovak, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.

A. Krishnan, J. Wright, P. Frankel, 2006 .

J. Rowley, M. Slovak, D. Arber, 2002, American journal of clinical pathology.

Diffuse large B-cell lymphoma

L. Popplewell, 2017 .

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

M. Kersten, P. Riedell, R. Malladi, 2020, Transplantation and Cellular Therapy.

Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.

M. Kersten, P. Riedell, M. Dreyling, 2021 .

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Nademanee, D. Gandara, P. Frankel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

W. Chan, D. Weisenburger, A. Nademanee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A. Goy, M. Palomba, E. Penuel, 2015 .

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

M. Kersten, P. Riedell, R. Malladi, 2021, Blood.

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

L. Staudt, W. Wilson, T. Phillips, 2015 .

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma

W. Plunkett, R. Chen, W. Wierda, 2008 .

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

M. Kersten, P. Riedell, R. Malladi, 2022, Blood.

Factors associated with high burden in caregivers of older adults with cancer

S. Forman, M. Loscalzo, K. Clark, 2014, Cancer.

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

M. Davids, A. Kittai, T. Siddiqi, 2021, Blood.

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

K. Savage, B. Coiffier, P. Zinzani, 2008 .

Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

W. Chan, Xiwei Wu, L. Kwak, 2019, Clinical Cancer Research.

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA (NHL)

F. Morschhauser, M. Palomba, G. Cartron, 2017 .

A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA

Craig B. Davis, R. Houot, S. Patel, 2017 .

Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer.

H. Cohen, D. Cella, M. Fakih, 2016, Journal of oncology practice.

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.

Kyuwan Lee, S. Forman, T. Siddiqi, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.

M. Slovak, S. Forman, R. Bhatia, 2004 .

Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma.

L. Kwak, S. Rosen, S. Kambhampati, 2022, Blood.

Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma

A. Krishnan, P. Frankel, G. Somlo, 2006, Bone Marrow Transplantation.

Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).

A. Nademanee, L. Kwak, S. Rosen, 2022, Blood.

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

A. Nademanee, L. Kwak, S. Rosen, 2019, Blood.

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

L. Kwak, S. Rosen, S. Forman, 2023, Haematologica.

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

K. Savage, L. Kwak, S. Rosen, 2021, Blood.

Targeted total marrow irradiation using 3D image guided tomographic intensity modulated radiation therapy: An alternative to standard TBI

An Liu, T. Schultheiss, J. Wong, 2006 .

Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation

D. Weisenburger, A. LaCasce, A. Nademanee, 2015 .

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

L. Kwak, S. Rosen, S. Forman, 2019, Blood.

Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy.

S. Horwitz, E. Jacobsen, O. O’Connor, 2009 .

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

M. Kaminski, S. Carty, P. Boonstra, 2023, Blood advances.

Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

A. Krishnan, T. Schultheiss, J. Wong, 2010, Clinical Cancer Research.

The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.

M. Kaminski, S. Carty, S. Malek, 2021 .

Circulating reactive plasma cells in the setting of peripheral T-cell lymphoma mimicking plasma cell leukemia.

L. Popplewell, J. Song, 2015, Blood.

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Scott E. Smith, R. Larson, W. Stock, 2009 .

Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.

A. Verma, H. Kantarjian, J. Cortes, 2011, Journal of Clinical Oncology.

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

K. Savage, B. Coiffier, S. Horwitz, 2010 .

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

L. Kwak, S. Forman, H. Lee, 2022, Blood.

PILLAR-1: Preliminary Results of a Phase II Study of mTOR Inhibitor Everolimus In Patients with Mantle Cell Lymphoma (MCL) Who Are Refractory or Intolerant to Bortezomib

Michael L. Wang, J. Winter, O. O’Connor, 2010 .

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Scott E. Smith, R. Larson, W. Stock, 2013, Clinical Cancer Research.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

M. Kalos, S. Forman, M. Jensen, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

A. Krishnan, P. Frankel, G. Somlo, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants.

K. Chang, S. Forman, A. Nademanee, 2004 .

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

S. Ong, R. Spielberger, J. Zain, 2023, American journal of hematology.

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

S. Ferrari, C. Haioun, C. Tam, 2021, Blood.

Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade.

Lei Gao, L. Kwak, S. Rosen, 2023, Blood.

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA

S. Forman, T. Siddiqi, J. Zain, 2019, Hematological Oncology.

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.

I. Aldoss, V. Pullarkat, A. Herrera, 2024, Leukemia & lymphoma.

S867 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

R. Advani, A. LaCasce, I. Flinn, 2019, HemaSphere.